Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research ...

Merck, known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International ...

Merck has been at the forefront of innovation in HIV for decades, and we are excited to continue contributing to HIV research by exploring the development of longer-acting treatment and prevention ...

RAHWAY, N.J. - Pharmaceutical giant Merck (NYSE:MRK), with a market capitalization of $203 billion and impressive 77% gross profit margin, will present new data from its HIV research pipeline at ...

Merck will share updates on new scientific findings from its HIV research program, including Phase 1 results from a trial evaluating the potential for drug-drug interaction between MK-8527, the ...

“ Merck remains at the forefront of research to develop new medicines for people living with HIV. The new data we will present at HIV Glasgow 2020 from our HIV research programs – for ...

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025. Merck (NYSE: MRK), known as MSD outside of the United States and Canada ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be ...

Merck, known as MSD outside of the United States and Canada, announced that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International AIDS ...

Merck, known as MSD outside the United States and Canada, announced today upcoming presentations from its HIV clinical development programs that will be featured during the 2021 Conference on ...

We look forward to sharing updates from our broad HIV program at CROI,” said Dr. Joan Butterton, vice president, global clinical development, infectious diseases, Merck Research Laboratories. “Our ...